Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Lyell Immunopharma (NASDAQ: LYEL) with a Buy rating and ...
On September 15, 2025, Charles Newton notified Lyell Immunopharma, Inc. (the "Company") of his decision to resign from ...
PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator's choice of approved CD19 CAR T-cell ...
Lyell Immunopharma (NASDAQ:LYEL) reported quarterly losses of $(2.89) per share which beat the analyst consensus estimate of $(...
